Management of Resistance to Targeted Therapy in EGFR Mutational Lung Adenocarcinoma: A Case Report
DOI:
https://doi.org/10.37275/bsm.v7i2.779Keywords:
Rebiopsy, RECIST, Resistance, TKIAbstract
Advances in diagnosis and treatment have enabled a targeted therapy approach to inhibit tumor progression and provide a favorable prognosis. One of the targeted therapies in non-small cell lung cancer (NSCLC) is tyrosine kinase inhibitor (TKI) in mutations epidermal growth factor receptor (EGFR). This study aimed to present a case with the management of resistance to targeted therapy in EGFR-mutated lung adenocarcinoma. Data shows median progression-free survival patients on TKI therapy at 10 to 14 months. Progressive caused by resistance to TKI and assessed using response evaluation criteria in solid tumors (RECIST) 1.1. and confirmed by repeat biopsy. Reported a male patient aged 66 years with adenocarcinoma of the right lung EGFR deletion exon 19 mutation and received afatinib therapy for 16 months. Patients experience oligo progressive in the 13th month of therapy and systemic progression 16th month.
Authors
- Armiza1*
- Sabrina Ermayanti1
- Afriani 1
- 1Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
Corresponding author Armiza — armizadokter@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
